The Company that Advised Itself

Last night as my plane leveled off at 30,000 ft I decided to get stuck into a glass of wine and the Biotech Daily. While flicking through the bioscience news de jour, I saw the following comment about IQ3 Group (ASX : IQ3): IQ3 says it has been appointed as corporate advisor to the Iqnovate agreement to…

BLT : How Not to Raise Money

Firstly, I want to start this post by sincerely congratulating Peter French and the Benitec (ASX : BLT) team for pricing their IPO. I don’t really like most of what this company does but you have to hand it to them for their tenacity and I genuinely admire the staying power. I think a lot of…

No Delirium in Adherium

Well, by now, the cat is out of the bag… and we know that Adherium successfully raised $35m in an oversubscribed share offer, and will list on the ASX (subject to regulator approval) on the 26th of August. It’s sort of nice to see our brethren from across the Tasman come up with something innovative…

Entrepreneurs, take heart…

Any of you reading this who has ever raised money or been on the road, been involved in business development or sales, will know the feeling I am about to describe. After a very excellent day of meetings in Sydney, mostly around raising some philanthropic funds for a project I am working on, I got to…

BLT IPO v 2.0

By now many readers are aware of the circumstances around Benitec’s (ASX : BLT) NASDAQ debut. As I reported last week, they failed to garner sufficient interest last week to price, reflected in their amended F-1 filing. The main thing to note about this filing is that the amount of capital to be raised is…

Benitec Fails to Fly

Well, after an intense week of waiting for Benitec (ASX : BLT / NASDAQ : BNTC) shareholders, we now know that BLT failed to fly. It’s had relatively mute coverage but I have heard fairly consistent feedback through my US investor network. The first bit of info is that BLT didn’t have remotely the subscription demand it needed to price…